Pioglitazone’s Have an effect on on Hepatic PPAR γ-Regulated Mitochondrial Gene

Willpower of genetic variation contained in the DYRK2gene and its associations with milk traits in cattle

 

To rush up the progress of marker-assisted alternative (MAS) in cattle breeding, the dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2), cadherin 2 (CDH2), and kinesin member of the household 1A (KIF1A) genes had been chosen based mostly totally on our pervious genome-wide affiliation study (GWAS) analysis outcomes. DYRK2 is a kinase that can participate in cell progress and/or progress; it reveals phosphorylation train in the direction of serine, threonine, and tyrosine fragments of proteins, and it is utterly totally different from totally different protein kinases. The CDH2 gene encodes a standard cadherin, which is a member of the cadherin superfamily.

 

The protein encoded by KIF1A is a member of the kinesin family and performs a activity inside the transportation of membrane organelles alongside axon microtubules. We detected insertion/deletion (InDel) variation in these three candidate genes in 438 explicit particular person cattle (Xinjiang Brown cattle and Wagyu × Luxi crossbreed cattle). Solely DYRK2-P3-11 bp was polymorphic and genotyped.

The polymorphism information content material materials of DYRK2-P3-11 bp was 0.336. Correlation analyses confirmed that InDel polymorphism was significantly associated to 6 utterly totally different milk traits. These findings may assist future analyses of InDelgenotypes in cattle breeds, and tempo up the progress of MAS in cattle breeding.

abeurope

abeurope

AKT Kinase Inhibitor
A3150-5 5 mg
EUR 819.6
Description: AKT Kinase Inhibitor

AKT Kinase Inhibitor
A3150-5.1 10 mM (in 1mL DMSO)
EUR 895.2
Description: AKT Kinase Inhibitor

AKT Kinase Inhibitor
HY-10249A 10mg
EUR 1052.4

Tie2 kinase inhibitor
A5979-100 100 mg
EUR 1452
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor
A5979-25 25 mg
EUR 477.6
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor
A5979-5 5 mg
EUR 199.2
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 kinase inhibitor
A5979-5.1 10 mM (in 1mL DMSO)
EUR 536.4
Description: IC50: A reversible and selective inhibitor of Tie2 with IC50 of 0.25 M, whose selectivity is 200-fold higher than that of p38.

Tie2 Kinase Inhibitor
B1338-25 each
EUR 907.2

Tie2 Kinase Inhibitor
B1338-5 each
EUR 314.4

Tie2 kinase inhibitor
E1KS1577 10mg
EUR 1849.2

K252A (Kinase inhibitor)
SIH-455-100UG 100 µg
EUR 157.2
  • K252A is a non-selective protein kinase inhibitor that exhibits a wide range of effects. Specifically, it has been seen to inhibit PKA, PKC, PKG, CAM kinase II, mlCK, Ser/Thr kinase, Met, and receptor tyrosine kinases. It has been shown to prevent au
  • Show more
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252A (Kinase inhibitor)
SIH-455-1MG 1 mg
EUR 358.8
  • K252A is a non-selective protein kinase inhibitor that exhibits a wide range of effects. Specifically, it has been seen to inhibit PKA, PKC, PKG, CAM kinase II, mlCK, Ser/Thr kinase, Met, and receptor tyrosine kinases. It has been shown to prevent au
  • Show more
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.

K252B (Kinase inhibitor)
SIH-456-100UG 100 µg
EUR 218.4
  • K252B is a non-selective, protein kinase inhibitor. It inhibits CaMKII, MYLK, PKA, PKC, and cGKI. It acts by binding to the ATP binding domain of the kinase. K252B is cell permeable.
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

K252B (Kinase inhibitor)
SIH-456-1MG 1 mg
EUR 682.8
  • K252B is a non-selective, protein kinase inhibitor. It inhibits CaMKII, MYLK, PKA, PKC, and cGKI. It acts by binding to the ATP binding domain of the kinase. K252B is cell permeable.
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).

MAPKII Kinase Inhibitor
abx076811-1mg 1 mg
EUR 376.8
  • Shipped within 5-12 working days.

Sorafenib (Raf-1 kinase inhibitor)
SIH-476-10MG 10 mg
EUR 145.2
  • Sorafenib display inhibition of multiple kinase targets including, VEGFR, PDGFR, and Raf.
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Sorafenib (Raf-1 kinase inhibitor)
SIH-476-50MG 50 mg
EUR 346.8
  • Sorafenib display inhibition of multiple kinase targets including, VEGFR, PDGFR, and Raf.
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).

Tyrosine kinase inhibitor
HY-10421 25mg
EUR 459.6

Dasatinib (Kinase inhibitor)
SIH-440-25MG 25 mg
EUR 238.8
  • Dasatinib is a dual Src and Abl kinase inhibitor with ?325 times more potency against BCR-ABL than imatinib. Specifically, it inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner.
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

Dasatinib (Kinase inhibitor)
SIH-440-5MG 5 mg
EUR 160.8
  • Dasatinib is a dual Src and Abl kinase inhibitor with ?325 times more potency against BCR-ABL than imatinib. Specifically, it inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner.
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).

IKK-? Kinase Inhibitor II
1811-1 each
EUR 189.6

IKK-? Kinase Inhibitor II
1811-5 each
EUR 574.8

RIP2 kinase inhibitor 2
HY-19761 50mg
EUR 2539.2

PP1 (Src kinase inhibitor)
SIH-469-25MG 25 mg
EUR 742.8
  • PP1 is a potent and selective Src family protein tyrosine kinase inhibitor. This has a range of effects and implications. Structural studies have revealed that PP1 binds to the ATP-binding site in tyrosine kinases and Ser/Thr kinases. PP1 displays >
  • Show more
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP1 (Src kinase inhibitor)
SIH-469-5MG 5 mg
EUR 246
  • PP1 is a potent and selective Src family protein tyrosine kinase inhibitor. This has a range of effects and implications. Structural studies have revealed that PP1 binds to the ATP-binding site in tyrosine kinases and Ser/Thr kinases. PP1 displays >
  • Show more
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.

PP2 (Src kinase inhibitor)
SIH-470-25MG 25 mg
EUR 884.4
  • PP2 is a selective inhibitor of Src-family tyrosine kinases. PP2 has been shown to inhibit Lck, FynT, and phosphorylation of focal adhesion kinase (FAK) and potently inhibits Hck, Lck (p56) and Fyn (p59). PP2 displays > 10000-fold selectivity over ZA
  • Show more
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

PP2 (Src kinase inhibitor)
SIH-470-5MG 5 mg
EUR 279.6
  • PP2 is a selective inhibitor of Src-family tyrosine kinases. PP2 has been shown to inhibit Lck, FynT, and phosphorylation of focal adhesion kinase (FAK) and potently inhibits Hck, Lck (p56) and Fyn (p59). PP2 displays > 10000-fold selectivity over ZA
  • Show more
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).

C16 (PKR kinase inhibitor)
SIH-498-25MG 25 mg
EUR 420
  • C16 is a derivative of imidazolo-oxindole and inhibits RNA-dependent protein kinases (PKR). Its inhibition effect on PKR is ATP-binding site directed. C16 has been shown to specifically inhibit the apoptotic PKR/eIF2a signaling pathway.
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

C16 (PKR kinase inhibitor)
SIH-498-5MG 5 mg
EUR 164.4
  • C16 is a derivative of imidazolo-oxindole and inhibits RNA-dependent protein kinases (PKR). Its inhibition effect on PKR is ATP-binding site directed. C16 has been shown to specifically inhibit the apoptotic PKR/eIF2a signaling pathway.
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .

Midostaurin (Kinase inhibitor)
SIH-468-1MG 1 mg
EUR 205.2
  • Midostaurin is a broad spectrum protein kinase inhibitor. It also shows inhibition of PKC?, PKC? and PKC? isoforms, Flk, and c-kit. Midostaurin displays antiproliferative characteristics and the ability to induce apoptosis.
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Midostaurin (Kinase inhibitor)
SIH-468-5MG 5 mg
EUR 608.4
  • Midostaurin is a broad spectrum protein kinase inhibitor. It also shows inhibition of PKC?, PKC? and PKC? isoforms, Flk, and c-kit. Midostaurin displays antiproliferative characteristics and the ability to induce apoptosis.
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).

Aurora Kinase Inhibitor 3
HY-112373 1mg
EUR 198

6BIO (PDK1 kinase inhibitor)
SIH-422-25MG 25 mg
EUR 474
  • 6BIO is an inhibitor of phosphoinositide-dependent kinase 1 (PDK1), and a potent, reversible and ATP-competitive inhibitor of glycogen synthase kinase-3?/? (GSK-3?/?). It maintains self-renewal and pluripotency in embryonic stem cells via activation
  • Show more
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

6BIO (PDK1 kinase inhibitor)
SIH-422-5MG 5 mg
EUR 178.8
  • 6BIO is an inhibitor of phosphoinositide-dependent kinase 1 (PDK1), and a potent, reversible and ATP-competitive inhibitor of glycogen synthase kinase-3?/? (GSK-3?/?). It maintains self-renewal and pluripotency in embryonic stem cells via activation
  • Show more
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.

LYS6K2 (S6 kinase inhibitor)
SIH-462-25MG 25 mg
EUR 582
  • LYS6K2 is a selective inhibitor of the p70 ribosomal S6 kinase. Specifically, it blocks the phosphorylation of S6. LYS6K2 is cell permeable.
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

LYS6K2 (S6 kinase inhibitor)
SIH-462-5MG 5 mg
EUR 205.2
  • LYS6K2 is a selective inhibitor of the p70 ribosomal S6 kinase. Specifically, it blocks the phosphorylation of S6. LYS6K2 is cell permeable.
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).

Aurora Kinase Inhibitor III
B7947-.5 500 µg
EUR 141.6
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III
B7947-1 1 mg
EUR 214.8
Description: Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III
B7947-5 5 mg
EUR 714
Description: Aurora Kinase Inhibitor III

KT5720 (PKA kinase inhibitor)
SIH-457-100UG 100 µg
EUR 246
  • KT5720 is a potent and selective inhibitor of protein kinase A (PKA). This compound blocks PKA signaling through competitive inhibition. It causes no significant effect on protein kinase C (PKC), protein kinase G (PKG) or myosin light chain kinase (m
  • Show more
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

KT5720 (PKA kinase inhibitor)
SIH-457-500UG 500 µg
EUR 682.8
  • KT5720 is a potent and selective inhibitor of protein kinase A (PKA). This compound blocks PKA signaling through competitive inhibition. It causes no significant effect on protein kinase C (PKC), protein kinase G (PKG) or myosin light chain kinase (m
  • Show more
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.

ml167 (Clk4 kinase inhibitor)
SIH-505-25MG 25 mg
EUR 608.4
  • ml167 is a highly selective inhibitor of Cdc2-like kinase 4 (Clk4). The Cdc2-like kinases are involved in regulation of gene splicing.
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

ml167 (Clk4 kinase inhibitor)
SIH-505-5MG 5 mg
EUR 205.2
  • ml167 is a highly selective inhibitor of Cdc2-like kinase 4 (Clk4). The Cdc2-like kinases are involved in regulation of gene splicing.
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .

GW2580 (cFMS kinase inhibitor)
SIH-449-25MG 25 mg
EUR 447.6
  • GW2580 is a potent and selective, ATP-competitive inhibitor of cFMS kinase. It also inhibits macrophage-colony stimulating factor receptor, M-CSF/ CSF-1. cFMS is a type III receptor tyrosine kinase that binds to M-CSF or CSF-1. Overexpression of CSF-
  • Show more
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

GW2580 (cFMS kinase inhibitor)
SIH-449-5MG 5 mg
EUR 168
  • GW2580 is a potent and selective, ATP-competitive inhibitor of cFMS kinase. It also inhibits macrophage-colony stimulating factor receptor, M-CSF/ CSF-1. cFMS is a type III receptor tyrosine kinase that binds to M-CSF or CSF-1. Overexpression of CSF-
  • Show more
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .

PD98059 (MEK kinase inhibitor)
SIH-466-25MG 25 mg
EUR 514.8
  • PD98059 is a potent, selective and reversible inhibitor of mitogen-activated protein kinase kinase (MAPKK/ MEK-1) activation. Specifically, it binds to the inactive form of MAPKK, blocking its activation, causing inhibition of phosphorylation and the
  • Show more
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

PD98059 (MEK kinase inhibitor)
SIH-466-5MG 5 mg
EUR 184.8
  • PD98059 is a potent, selective and reversible inhibitor of mitogen-activated protein kinase kinase (MAPKK/ MEK-1) activation. Specifically, it binds to the inactive form of MAPKK, blocking its activation, causing inhibition of phosphorylation and the
  • Show more
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).

AZD6244 (ERK kinase inhibitor)
SIH-495-25MG 25 mg
EUR 716.4
  • AZD6244 is a MEK-1 inhibitor. Specifically, AZD6244 inactivates the phosphorylation of ERK1/2.
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

AZD6244 (ERK kinase inhibitor)
SIH-495-5MG 5 mg
EUR 252
  • AZD6244 is a MEK-1 inhibitor. Specifically, AZD6244 inactivates the phosphorylation of ERK1/2.
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).

SRPIN340 (SR kinase inhibitor)
SIH-514-25MG 25 mg
EUR 481.2
  • SRPIN340 is a selective inhibitor of serine?arginine protein kinases (SRPK). It has been shown to inhibit SRPK1, as well as, SRPK2, at higher concentrations. SRPIN340 is ATP-competitive.
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

SRPIN340 (SR kinase inhibitor)
SIH-514-5MG 5 mg
EUR 178.8
  • SRPIN340 is a selective inhibitor of serine?arginine protein kinases (SRPK). It has been shown to inhibit SRPK1, as well as, SRPK2, at higher concentrations. SRPIN340 is ATP-competitive.
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.

AG1296 (PDGFR kinase inhibitor)
SIH-426-25MG 25 mg
EUR 608.4
  • AG-1296 is a potent and specific inhibitor of PDGF receptor tyrosine kinase. AG-1296 is cell-permeable.
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

AG1296 (PDGFR kinase inhibitor)
SIH-426-5MG 5 mg
EUR 205.2
  • AG-1296 is a potent and specific inhibitor of PDGF receptor tyrosine kinase. AG-1296 is cell-permeable.
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.

SU1498 (VEGFR kinase inhibitor)
SIH-480-25MG 25 mg
EUR 447.6
  • SU1498 is a potent and selective inhibitor of Flk-1, a VEGF receptor kinase, and VEGFR2.
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

SU1498 (VEGFR kinase inhibitor)
SIH-480-5MG 5 mg
EUR 169.2
  • SU1498 is a potent and selective inhibitor of Flk-1, a VEGF receptor kinase, and VEGFR2.
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .

PD325901 (MEK kinase inhibitor)
SIH-507-25MG 25 mg
EUR 554.4
  • PD325901 is a potent MEK1 and MEK2 inhibitor. Specifically, it has been shown to suppress phosphorylation of ERK1/2 in murine colon 26 cells, as well as, its downstream target, ribosomal S6 kinase, in a dose-dependent manner.
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PD325901 (MEK kinase inhibitor)
SIH-507-5MG 5 mg
EUR 205.2
  • PD325901 is a potent MEK1 and MEK2 inhibitor. Specifically, it has been shown to suppress phosphorylation of ERK1/2 in murine colon 26 cells, as well as, its downstream target, ribosomal S6 kinase, in a dose-dependent manner.
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.

PHA 665752 (MET kinase inhibitor)
SIH-421-25MG 25 mg
EUR 696
  • PHA 665752 is a potent and selective MET kinase, ATP-competitive inhibitor. It has been studied as an antitumor agent because it has been seen to inhibit tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

PHA 665752 (MET kinase inhibitor)
SIH-421-5MG 5 mg
EUR 231.6
  • PHA 665752 is a potent and selective MET kinase, ATP-competitive inhibitor. It has been studied as an antitumor agent because it has been seen to inhibit tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .

A83 01 (ALK kinase inhibitor)
SIH-423-25MG 25 mg
EUR 514.8
  • A83-01 is a selective inhibitor of TGF-? type I receptor ALK5 kinase. It blocks phosphorylation of Smad2 and inhibits TGF-?-induced epithelial-to-mesenchymal transition. A 83-01 also inhibits the transcriptional activity induced by TGF? type I recept
  • Show more
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

A83 01 (ALK kinase inhibitor)
SIH-423-5MG 5 mg
EUR 187.2
  • A83-01 is a selective inhibitor of TGF-? type I receptor ALK5 kinase. It blocks phosphorylation of Smad2 and inhibits TGF-?-induced epithelial-to-mesenchymal transition. A 83-01 also inhibits the transcriptional activity induced by TGF? type I recept
  • Show more
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)
SIH-438-25MG 25 mg
EUR 514.8
  • CID 2011756 is a specific, ATP-competitive protein kinase D inhibitor. It is also cell permeable.
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

CID 2011756 (PKD kinase inhibitor)
SIH-438-5MG 5 mg
EUR 184.8
  • CID 2011756 is a specific, ATP-competitive protein kinase D inhibitor. It is also cell permeable.
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.

KT 5823 (PKG kinase inhibitor)
SIH-458-100UG 100 µg
EUR 246
  • KT5823 is a potent, selective, and reversible inhibitor of Protein Kinase G (PKG). It is a derivative of K-252a. KT5823 has been shown to inhibit SNP-stimulated PKG activity in dispersed smooth muscle cells. It has also been observed to dose-dependen
  • Show more
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

KT 5823 (PKG kinase inhibitor)
SIH-458-500UG 500 µg
EUR 682.8
  • KT5823 is a potent, selective, and reversible inhibitor of Protein Kinase G (PKG). It is a derivative of K-252a. KT5823 has been shown to inhibit SNP-stimulated PKG activity in dispersed smooth muscle cells. It has also been observed to dose-dependen
  • Show more
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).

NPC 15437 (PKC kinase inhibitor)
SIH-464-1MG 1 mg
EUR 205.2
  • NPC 15437 is selective inhibitor of protein kinase C (PKC). Specifically, it interacts with regulatory domain at residues 12-42.
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.

Genetic variants in N6-methyladenosine are associated to bladder most cancers risk inside the Chinese language language inhabitants

 

Not too way back N6-Methyladenosine (m6A) has been acknowledged to info the interaction of RNA-binding protein hnRNP C and their purpose RNAs, which is termed as m6A-switches. We systematically investigated the affiliation between genetic variants in m6A-switches and bladder most cancers risk. A two-stage case-control study was carried out to systematically calculate the affiliation of single nucleotide polymorphisms (SNPs) in 2798 m6A-switches with bladder most cancers risk in 3,997 subjects.

 

A logistic regression model was used to guage the outcomes of SNPs on bladder most cancers risk. A group of experiments had been adopted to find the operate of genetic variants of m6A-switches. We acknowledged that rs5746136 (G > A) of SOD2 in m6A-switches was significantly associated to the diminished risk of bladder most cancers (additive model in discovery stage: OR = 0.80, 95% CI 0.69-0.93, P = 3.6 × 10-3; validation stage: adjusted OR = 0.88, 95% CI 0.79-0.99, P = 3.0 × 10-2; combined analysis: adjusted OR = 0.85, 95% CI 0.78-0.93, P = 4.0 × 10-4).

 

The mRNA stage of SOD2 was remarkably lower in bladder most cancers tissues than the paired adjoining samples. SNP rs5746136 may affect m6A modification and regulate SOD2 expression by guiding the binding of hnRNP C to SOD2, which carried out a important tumor suppressor operate in bladder most cancers cells by promoting cell apoptosis and inhibiting proliferation, migration and invasion.

 

In conclusion, our findings counsel the important operate of genetic variants in m6A modification. SOD2 polymorphisms may have an effect on the expression of SOD2 by an m6A-hnRNP C-dependent mechanism and be promising predictors of bladder most cancers risk.

Weight reduction plan Modifies Pioglitazone’s Have an effect on on Hepatic PPAR γ-Regulated Mitochondrial Gene Expression

 

 

  • Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose outcomes finish outcome predominantly from its modulation of the transcriptional train of peroxisome proliferator-activated-receptor-gamma (PPARγ). Pio is used to cope with human insulin-resistant diabetes and as well as ceaselessly thought-about for remedy of nonalcoholicsteatohepatitis (NASH).

 

  • In every settings, Pio’s useful outcomes are believed to finish outcome primarily from its actions on adipose PPARγ train, which improves insulin sensitivity and reduces the provision of fatty acids to the liver. Nonetheless, a modern medical trial confirmed variable efficacy of Pio in human NASH.

 

  • Hepatocytes moreover particular PPARγ, and such expression will improve with insulin resistance and in nonalcoholic fatty liver sickness (NAFLD). Furthermore, mice that overexpress hepatocellular PPARγ and Pio-treated mice with extrahepatic PPARγ gene disruption develop choices of NAFLD. Thus, Pio’sdirect affect on hepatocellular gene expression may be a determinant of this drug’s remaining have an effect on on insulin resistance and NAFLD. Earlier analysis have characterised Pio’sPPARγ-dependent outcomes on hepatic expression of explicit adipogenic, lipogenic, and totally different metabolic genes.

 

  • Nonetheless, such transcriptional regulation has not been comprehensively assessed. The analysis reported proper right here cope with that consideration by genome-wide comparisons of Pio’s hepatic transcriptional ends in wildtype (WT) and liver-specific PPARγ-knockout (KO) mice given each administration or high-fat (HFD) diets. The outcomes set up an enormous set of hepatic genes for which Pio’s liver PPARγ-dependent transcriptional outcomes are concordant with its outcomes on RXR-DNA binding in WT mice.

 

  • These info moreover current that HFD modifies Pio’s have an effect on on a subset of such transcriptional regulation. Lastly, our findings reveal a broader have an effect on of Pio on PPARγ-dependent hepatic expression of nuclear genes encoding mitochondrial proteins than beforehand acknowledged. Taken collectively, these analysis current new insights regarding the tissue-specific mechanisms by which Pio impacts hepatic gene expression and the broad scope of this drug’s have an effect on on such regulation.

 

HIV Type 1 p24 Antigen ELISA (96 Determinations)
0801111 96T
EUR 621

HIV Type 1 p24 Antigen ELISA (96 Determinations)
801111 96 Determinations
EUR 591

HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations)
801002 96 Determinations
EUR 574

HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations)
0801002 96T
EUR 603

HIV-P24 antigen array kit
VArk-Lsx001 unit Ask for price
Description: Fourth-generation HIV immunoassays detect viral p24 protein in the blood.

HIV-1 GAG P24 Recombinant Antigen
00111-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 GAG P24 Recombinant Antigen
00111-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV 1 p24 core recombinant antigen
00177-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV 1 p24 core recombinant antigen.

HIV 1 p24 core recombinant antigen
00177-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV 1 p24 core recombinant antigen.

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)
0801200 5 X 96T
EUR 2563

HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations)
801200 5 X 96 Determinations
EUR 2330

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)
801008 5 X 96 Determinations
EUR 2386

HIV Type 1 p24 Antigen ELISA 2.0 (5 X 96 Determinations)
0801008 5 X 96T
EUR 2505

Human HIV(1+2 antibodies plus p24 antigen (4th Generation) ELISA Kit
EH4101 96T
EUR 571.5
  • Detection range: Qualitative
Description: Method of detection: Qualitative ;Reacts with: Homo sapiens;Sensitivity: Qualitative

HIV-1 p24 ELISA Kit
Z7040001 1 kit
EUR 752

HIV-1 p17/24/gp120 antigen
00169-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 p17/24/gp120 antigen
00169-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 p17/24/gp120 antigen.The protein contains the HIV immunodominant regions from gag p17-p24 gp 120.

HIV-1 intergase antigen
00199-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 intergase antigen
00199-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 intergase antigen. The protein contains the HIV-1 immunodominant regions from pol protein (integrase).

HIV-1 p24 Antibody
7313-002mg 0.02 mg
EUR 206.18
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody
7313-01mg 0.1 mg
EUR 523.7
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.

HIV-1 p24 Antibody
abx023027-1ml 1 ml
EUR 693.6
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx023925-1mg 1 mg
EUR 828
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx023926-1mg 1 mg
EUR 828
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021869-1mg 1 mg
EUR 794.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021870-1mg 1 mg
EUR 760.8
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021871-1mg 1 mg
EUR 794.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021872-1mg 1 mg
EUR 794.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021873-1mg 1 mg
EUR 794.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021882-1mg 1 mg
EUR 1178.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021883-1mg 1 mg
EUR 1220.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021886-1mg 1 mg
EUR 1220.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021887-1mg 1 mg
EUR 1220.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
abx021888-1mg 1 mg
EUR 1220.4
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody
20-abx137062
  • EUR 427.2
  • EUR 627.6
  • 0.5 mg
  • 1 mg
  • Shipped within 5-10 working days.

HIV-1 p24
E5-00024 1mg
EUR 1152

HIV-1 p24
E62H002 100ug
EUR 458.4

HIV-1 tat recombinant antigen
00110-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 tat recombinant antigen
00110-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 nef recombinant antigen
00112-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 nef recombinant antigen
00112-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 gag recombinant antigen
8934 100 ug
EUR 542.86
Description: This is HIV-1 gag recombinant antigen for ELISA,WB.

HIV-1 nef recombinant antigen
8941 100 ug
EUR 477.6
Description: This is HIV-1 nef recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen,
00170-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen,
00170-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 gp41 recombinant antigen.

HIV-1 gp41 recombinant antigen
8908 100 ug
EUR 673.36
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen
8933 100 ug
EUR 477.6
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen
9000 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV-1 gp41 recombinant antigen
9001 100 ug
EUR 484.13
Description: This is HIV-1 gp41 recombinant antigen for ELISA,WB.

HIV p24 Antibody
abx021867-1mg 1 mg
EUR 1612.8
  • Shipped within 5-10 working days.

HIV p24 Antibody
abx021868-1mg 1 mg
EUR 1612.8
  • Shipped within 5-10 working days.

HIV-1 p17/24/gp120-gp41 recombinant antigen,
00168-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV-1 p17/24/gp120-gp41 recombinant antigen,
00168-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 p17/24/gp120-gp41 recombinant antigen.

HIV 1 envelope recombinant antigen
00176-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

HIV 1 envelope recombinant antigen
00176-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV 1 envelope recombinant antigen. HIV-1 evnelope protein spanning the C-Terminus of gp 120 and most of gp 41.

ToX Antigen (P24,GRA1)
E61Y00305 1mg
EUR 840

HIV-1 env gp41 recombinant antigen
00113-V-01mg 0,1 mg
EUR 321
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 env gp41 recombinant antigen
00113-V-1000ug 1000 ug
EUR 1539
  • Category: Antigens, HIV-1/HIV-2, Ag
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 p24 Antibody (HRP)
abx023029-1ml 1 ml
EUR 886.8
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody [8G9]
PM-6335-002mg 0.02 mg
EUR 206.18
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [8G9]
PM-6335-01mg 0.1 mg
EUR 523.7
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]
PM-6585-002mg 0.02 mg
EUR 206.18
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody [7F4]
PM-6585-01mg 0.1 mg
EUR 523.7
  • Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).

HIV-1 p24 Antibody (FITC)
abx023026-1ml 1 ml
EUR 678
  • Shipped within 5-10 working days.

HIV-1 p24 Antibody (FITC)
abx021884-100ug 100 ug
EUR 886.8
  • Shipped within 5-10 working days.